MRKR

Marker Therapeutics, Inc. MRKR

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,664 of 2,925

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Top Institutional Holders

as of Q2 2026
$5.84M total
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/MRKR

Earnings Per Share

13fpro.ai/company/MRKR

Loading ratio trend…

MRKR key financials by period

Reported revenue, net income and operating margin by fiscal year, from Marker Therapeutics, Inc.'s annual filings on SEC EDGAR.

Marker Therapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$3.5M$-12.2M—
FY 2024$6.6M$-10.7M-168.7%
FY 2023$3.3M$-8.2M—
FY 2022$3.5M$-29.9M—
FY 2020$500.0K$-28.7M—
FY 2019$213.2K$-21.4M—
Source: MRKR filings on SEC EDGAR →

About Marker Therapeutics, Inc. (MRKR): stock profile, AI score and financials

Marker Therapeutics, Inc. (MRKR) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MRKR at 24.3/100 on a composite quality score built from its SEC filings, placing it at rank #2,664 of 2,925 stocks — the bottom half of the AI-ranked universe. Top institutional holders of MRKR by reported 13-F value include NEA Management Company, Blue Owl Capital, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. MRKR trades on the Nasdaq exchange and files with the SEC under CIK 1094038. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MRKR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Marker Therapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1094038 →